

## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010

## **CCL13 RABBIT PAB**

货号: S219685

产品全名: CCL13 兔多抗

基因符号 MCP-4, NCC1, CKb10, NCC-1, SCYL1, SCYA13 UNIPROT ID: Q99616 (Gene Accession - NP\_005399)

背景: This gene is one of several Cys-Cys (CC) cytokine genes clustered on the q-arm of chromosome 17. Cytokines are a family of secreted proteins involved in immunoregulatory and inflammatory processes. The CC cytokines are proteins characterized by two adjacent cysteines. The cytokine encoded by this gene displays chemotactic activity for monocytes, lymphocytes, basophils and eosinophils, but not neutrophils. This chemokine plays a role in accumulation of leukocytes during inflammation. It may also be involved in the recruitment of monocytes into the arterial wall during artherosclerosis.

抗原: Synthetic peptide of human CCL13

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 30-150; ELISA: 2000-10000

种属反应性: Rabbit 克隆性: Rabbit Polyclonal


亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification

种属反应性: Human


成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Immunology


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human thyroid cancer tissue using 219685(CCL13 Antibody) at a dilution of 1/40(Secreted).



In comparision with the IHC on the left, the same paraffin-embedded Human thyroid cancer tissue is first treated with the synthetic peptide and then with 219685(Anti-CCL13 Antibody) at dilution 1/40.



The image on the left is immunohistochemistry of paraffinembedded Human esophagus cancer tissue using 219685(Anti-CCL13 Antibody) at a dilution of 1/40.



In comparision with the IHC on the left, the same paraffin-embedded Human esophagus cancer tissue is first treated with synthetic peptide and then with D260146(Anti-CCL13 Antibody) at dilution 1/40.



## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010